Regorafenib active in metastatic GI stromal tumors - medicalxpress.com

(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according to a study published ...

A Few Thoughts On The actual Near Future For Doxorubicin - 1UP.COM

TKI to the other, either with sorafenib followed by sunitinib SoSu or sunitinib followed by sorafenib SuSo. Everolimus was associatedwith a median PFS of . months in the in general inhabitants versus . months for placebo hazard ratio HR . self confidence ...

Pfizer Provides Topline Results From Phase 3 Study Of Torisel(R) As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC) - Marketwatch

The combination of TORISEL and sunitinib resulted in dose-limiting toxicity (Grade 3/4 erythematous maculopapular rash, and gout/cellulitis requiring hospitalization). For more information on TORISEL, including full prescribing information for ...

AB SCIENCE : Recruitment of the First Patient for the Phase 3 Study on Gleevec®-Resistant GIST, Comparing Masitinib with Sunitinib - 4-traders (press release)

AB Science SA (Euronext Paris - FR0010557264 - AB)(Paris:AB), a pharmaceutical company specialized in research, development and commercialization of protein kinase inhibitors (PKI), announces today the recruitment of the first patient in a phase 3 study ...

Pfizer does not meet primary endpoint in TORISEL Phase 3 study for advanced RCC - News-Medical.Net

Pfizer Inc. announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL ® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT ® (sunitinib malate) therapy ...

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma - News-Medical.Net

after failure of prior treatment with sunitinib or a cytokine. “Despite recent advances in the treatment of advanced kidney cancer, there is a clear need for additional treatment options for patients whose disease has progressed following firs ...

Pfizer's Axitinib Gets Positive Opinion From CHMP - Quick Facts - NASDAQ

after failure of prior treatment with sunitinib or a cytokine. Axitinib, a kinase inhibitor, is an oral therapy that was designed to selectively inhibit tyrosine kinases, including vascular endothelial growth factor receptors 1, 2 and 3 ...

2 Dow 30 Stocks Enjoying the Bounce - Wall St. Cheat Sheet

The drug is aimed at the treatment of adult patients having advanced renal cell carcinoma, which is a type of advanced kidney cancer, subsequent to failure of prior treatment with sunitinib or a cytokine. The European Commission, which possesses the ...

Pfizer Reports Results From Phase 3 Study Of Torisel - Quick Facts - RTT News

(RTTNews) - Pfizer Inc (PFE: News ) announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL (temsirolimus) in patients with advanced renal cell carcinoma or RCC whose disease had progressed on or after SUTENT (sunitinib malate) therapy ...

Hot Stock Research for Pfizer, PepsiCo, Duke Energy, Regions Financial, Peabody Energy, and Renren - Sacramento Bee

in patients with advanced renal cell carcinoma or RCC whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not achieve the primary endpoint of prolonging progression free survival or PFS when compared to sorafenib.